Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Which vaccine messages grab attention in rural New England

Official title: ARISe at UMass Chan: Remote Eye Tracking Study of Vaccine Messaging in Rural Populations

Run by University of Massachusetts, Worcester · NCT07236034 · Data updated 2026-11-12

This online test uses short social-media vaccine messages delivered by either experts or influencers to see which ones better catch attention and influence attitudes among adults living in rural New England.

More Vaccination trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment700 (estimated)
SponsorUniversity of Massachusetts, Worcester
Academic / other
Locations1 site (Worcester, Massachusetts)
StatusRecruiting
StartedDecember 1, 2025
Main results expectedSeptember 30, 2026
Study endsDecember 30, 2026
Registry record updatedJuly 7, 2026
Trial IDNCT07236034 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 or older who live in a rural zip code in one of the New England states, can read and write English, and have access to an internet-connected computer or laptop with a webcam.

Probably not a fit

People under 18, those living outside the specified New England rural zip codes, non–English readers, or anyone without a compatible computer and webcam are unlikely to benefit from or be eligible for this project.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults in rural New England will be randomly assigned to one of 14 conditions combining two sources (expert vs influencer) with seven message themes from the 7C Vaccine Framework and will view sample social-media content. While participants view messages on a computer or laptop, remote eye-tracking software will record visual attention and participants will complete questionnaires about their attitudes and beliefs. The study combines eye-tracking metrics and self-reported perceptions to identify which message-source pairs attract attention and change responses. Findings are intended to guide more effective vaccine promotion tailored to rural communities.

Why it matters

Potential benefit: If successful, this work could identify message and source combinations that increase attention to vaccine information and improve vaccine attitudes in rural New England, potentially boosting vaccination rates.

How similar studies have gone: Previous work on message framing and source credibility has sometimes improved vaccine attitudes and eye-tracking has been useful for mapping attention, but using remote eye-tracking specifically for vaccine promotion in rural populations is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18+
* Living in New England state (CT, MA, ME, NH, VT RI) in a zip code as defined by each individual state's definition of rural
* Able to read and write in English
* Access to an internet connected computer or laptop with a web-camera

Exclusion Criteria:

* N/A

Where it's running

  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts, United States
    Recruiting

Study contacts

  • Principal investigator: Grace W Ryan, PhD, MPH — University of Massachusetts, Worcester
  • Study coordinator: Grace W Ryan, PhD, MPH
  • Email: grace.ryan1@umassmed.edu
  • Phone: 508-859-0179

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.